The effect of fibrate–statin combination therapy on cardiovascular events: a retrospective cohort analysis

The metabolic syndrome

(2010) Robert H Eckel et al.   LANCET

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

(2010) Min Jun et al.   LANCET

A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials

(2010) John Simes et al.   PLoS One

Triglycerides and Vascular Risk: Insights from Epidemiological Data and Interventional Studies

(2009) Konstantinos Tziomalos et al.   CURRENT DRUG TARGETS

Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia

(2009) Anthony S Wierzbicki   CURRENT OPINION IN CARDIOLOGY

Combination therapy of statins and fibrates in the management of cardiovascular risk

(2009) Catherine Fiévet et al.   CURRENT OPINION IN LIPIDOLOGY

The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

(2008) Jean-Charles Fruchart et al.   AMERICAN JOURNAL OF CARDIOLOGY

Ten-Year All-Cause Mortality in Presumably Healthy Subjects on Lipid-Lowering Drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort)

(2008) Virginie Gardette et al.   AMERICAN JOURNAL OF CARDIOLOGY

Effect of Fenofibrate on Kidney Function: A 6-Week Randomized Crossover Trial in Healthy People

(2008) Jean-Claude Ansquer et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?

(2008) Anthony Wierzbicki et al.   Current Vascular Pharmacology